Table 2. Summary of the meta analysis results.
| Outcome | Stratified analysis | No. of studies | No. of patients | Random-effects model |
Fixed-effects model |
Heterogeneity |
|||
|---|---|---|---|---|---|---|---|---|---|
| HR(95%CI) | P | HR(95%CI) | p | I2(%) | Ph | ||||
| OS | Treatment | ||||||||
| Surgery | 5 | 2197 | 1.70(1.39–2.10) | <0.001 | 1.10(1.05–1.15) | <0.001 | 85.2 | <0.001 | |
| Non-surgery | 8 | 1347 | 1.76(1.30–2.39) | <0.001 | 1.49(1.30–2.72) | <0.001 | 46.8 | 0.111 | |
| Country | |||||||||
| Western | 6 | 2017 | 1.74(1.44–2.12) | 0.001 | 1.70(1.46–1.99) | <0.001 | 82.4 | <0.001 | |
| Eastern | 7 | 1527 | 1.58(1.22–2.04) | <0.001 | 1.09(1.04–1.14) | <0.001 | 29.7 | 0.212 | |
| Tumor stage | |||||||||
| Early stage | 7 | 2350 | 1.69(1.37–2.10) | <0.001 | 1.55(1.36–1.77) | <0.001 | 48.8 | 0.068 | |
| Late stage | 6 | 1194 | 1.64(1.19–2.27) | 0.003 | 1.09(1.04–1.14) | <0.001 | 85.8 | <0.001 | |
| Sample size | |||||||||
| ≥200 | 6 | 2585 | 1.61(1.33–1.95) | <0.001 | 1.53(1.34–1.75) | <0.001 | 41.7 | 0.127 | |
| <200 | 7 | 959 | 1.76(1.26–2.44) | 0.001 | 1.09(1.04–1.14) | <0.001 | 84.8 | <0.001 | |
| Cut–off value | |||||||||
| =5 | 6 | 2257 | 1.67(1.44–1.94) | <0.001 | 1.67(1.44–1.94) | <0.001 | 0 | 0.506 | |
| ≠5 | 7 | 1287 | 1.67(1.26–2.23) | <0.001 | 1.09(1.04–1.14) | <0.001 | 84.2 | <0.001 | |
| NOS score | |||||||||
| ≥7 | 6 | 1517 | 1.46(1.14–1.86) | 0.002 | 1.09(1.04–1.14) | <0.001 | 82.2 | <0.001 | |
| <7 | 7 | 2027 | 1.83(1.56–2.15) | <0.001 | 1.83(1.56–2.15) | <0.001 | 0 | 0.498 | |
| PFS | Country | ||||||||
| Western | 5 | 1679 | 1.56(1.31–1.86) | <0.001 | 1.56(1.31–1.86) | <0.001 | 0 | 0.791 | |
| Eastern | 5 | 944 | 1.68(1.12–2.52) | 0.012 | 1.05(1.00–1.11) | 0.049 | 86.9 | <0.001 | |
| Sample size | |||||||||
| ≥200 | 3 | 1782 | 1.46(1.21–1.77) | <0.001 | 1.46(1.21–1.77) | <0.001 | 0 | 0.643 | |
| <200 | 7 | 841 | 1.72(1.20–2.46) | 0.003 | 1.06(1.01–1.12) | 0.019 | 84.5 | <0.001 | |
| Cut-off value | |||||||||
| =5 | 3 | 1567 | 1.54(1.27–1.86) | <0.001 | 1.54(1.27–1.86) | <0.001 | 0 | 0.453 | |
| ≠5 | 7 | 1056 | 1.67(1.19–2.35) | 0.003 | 1.06(1.01–1.12) | 0.027 | 82.7 | <0.001 | |
| NOS score | |||||||||
| ≥7 | 5 | 954 | 1.40(1.03–1.91) | 0.032 | 1.04(0.99–1.10) | 0.115 | 71 | 0.008 | |
| <7 | 5 | 1669 | 1.79(1.38–2.33) | <0.001 | 1.67(1.41–1.98) | <0.001 | 52.3 | 0.079 | |
Ph: p value of Q test for heterogeneity test; N: number of studies (cohorts); HR: hazard ratio; 95% CI: 95% confidence interval; For OS and PFS, subgroup analyses were performed by treatment (surgery vs. non-surgery), study location (Western vs. Eastern countries), sample size (≥200 vs.<200) ,cut-off value of NLR (5 vs. not 5) and NOS score(≥7 vs.<7).